- Medicine Name: Amvuttra
- API: Vutrisiran
- Dosage Form & Strength: Injection: 25 mg/0.5 mL in a single-dose prefilled syringe
- Manufactured By: Alnylam Pharmaceuticals, Inc
Amvuttra (vutrisiran) is a transthyretin-directed small interfering RNA widely used for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adults.
Recommended Dosage: The recommended dosage of Amvuttra is 25 mg administered by subcutaneous (SC) injection once every 3 months.
In case a dose is missed, administer as quickly as possible. Resume dosing with Amvuttra every 3 months from the most recently administered dose.
All Trademarks and Brands that appear on the website belong to their respective owners and indianpharmanetwork does not lay any claim on them we only provide Information.